Express congratulations!

▎The content team editor of WuXi AppTec recently, BridGene Biosciences announced that it has reached a research cooperation agreement with the Peter MacCallum Cancer Center (officially referred to as Peter Mac)
.

According to the agreement, Peter Mac and BridGene will establish a drug discovery program, through Peter Mac’s ovarian chemotherapy drug resistance phenotype screening technology, and BridGene’s proprietary chemical proteomics IMTAC (Isobaric Mass Tagged Affinity Characterization) technology platform.
A new target for the treatment of chemotherapy-resistant ovarian cancer and the development of small molecule drug candidates
.

Phenotypic screening is a powerful drug discovery tool that can detect compounds in cell or animal disease models, find those compounds that can cause ideal changes in the phenotype of disease-related cells, and discover new compounds for the treatment of diseases
.

However, researchers face considerable challenges in identifying the compound targets that drive disease
.

For a long time, many disease-driven targets have been considered "non-druggable" because their functional protein pockets are too shallow or are transiently formed in living cells, making it difficult for traditional high-throughput screening to develop drugs against such targets
.

Although traditional phenotypic screening can be carried out in living cells, it is extremely difficult to determine the target that causes phenotypic changes
.

BridGene's unique IMTAC technology platform can not only find small molecule ligands for a large number of targets (including "non-drugable" targets) in living cells; it can also be combined with phenotypic screening technology to determine targets that drive phenotypic changes and disease occurrence
.

Specifically, the IMTAC platform uses a unique drug-like covalent small molecule library and screens live cells.
Small molecules bind to some of the proteins in living cells
.

After that, quantitative mass spectrometry can analyze which protein binds to the small molecule and its relative binding affinity to identify the target (obtained through phenotypic screening) and its relative binding affinity in living cells that bind to the compound, so as to find that it can drive New targets for disease
.

BridGene is developing early-stage projects for potential treatments of several cancers, and is expected to submit a new drug clinical trial application (IND) to the US FDA in 2023
.

 ▲ IMTAC technology platform (picture source: BridGene's official website) Dr.
Cao Ping, co-founder and CEO of BridGene Biosciences, said: "This collaboration with researchers from Peter Mac represents an important milestone in BridGene's new drug discovery strategy.
The strategy combines phenotypic drug discovery (PDD) and target-based drug discovery (TDD)
.

This new method will effectively link new drugs, new targets and diseases, and create new Therapies and further validate the potential power of our chemical proteomics technology
.

We believe that the combination of the IMTAC platform and phenotypic screening technology can quickly and effectively discover compounds that can trigger disease reversal, and determine their biological targets, thereby Change the treatment model for patients with chemotherapy-resistant ovarian cancer and other difficult-to-treat diseases
.

"Reference: [1] BridGene Biosciences Announces Research Collaboration with the Peter MacCallum Cancer Centre to Discover Targets and Small Molecule Drug Candidates for Ovarian Cancer.
Retrieved December 17, 2021, from https:// /bridgene-biosciences-announces-research-collaboration-with-the-peter-maccallum-cancer-centre-to-discover-targets-and-small-molecule-drug-candidates-for-ovarian-cancer-301445186.
html?tc =eml_cleartime Disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.

This article is for information exchange purposes only.
The views in the article do not represent WuXi AppTec's position, nor do it mean that WuXi AppTec supports or opposes the views
in the
article .
This article also It is not a treatment plan recommendation
.

If you need treatment plan guidance, please go to a regular hospital for treatment
.